Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)

NCT05920798 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT05920798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05920798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MC220601, Folate Receptor Alpha Dendritic Cells (FRαDCs) Plus Pembrolizumab for Patients With Advanced Stage Ovarian Cancer (FRAPPE)
Lead sponsor
Mayo Clinic
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 28, 2023
Completion date
October 28, 2030
Enrollment
38 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube carcinosarcoma, primary peritoneal carcinosarcoma, recurrent fallopian tube carcinoma, recurrent fallopian tube clear cell adenocarcinoma, recurrent fallopian tube endometrioid adenocarcinoma, recurrent fallopian tube high grade serous adenocarcinoma, recurrent ovarian carcinoma, recurrent ovarian carcinosarcoma, recurrent ovarian clear cell adenocarcinoma, recurrent ovarian endometrioid adenocarcinoma, recurrent ovarian high grade serous adenocarcinoma, recurrent primary peritoneal carcinoma, recurrent primary peritoneal carcinosarcoma, recurrent primary peritoneal clear cell adenocarcinoma, recurrent primary peritoneal endometrioid adenocarcinoma, recurrent primary peritoneal high grade serous adenocarcinoma